Deep vein thrombosis and systemic inflammatory response: a pilot trial.

Introduction: Symptoms of deep vein thrombosis as swelling, erythema, pain and calor have been suspected of being caused by an inflammatory reaction of the affected leg. We therefore performed a prospective pilot trial to study a possible systemic inflammatory response induced by deep vein thrombosis.

Patients And Methods: We determined white blood cell count and plasma C-reactive protein in 100 consecutive patients with suspected deep vein thrombosis.

Idraparinux and liver enzymes: observations from the PERSIST trial.

A potential influence of idraparinux--a synthetic analogue of the pentasaccharide sequence in heparins--on plasma liver enzyme levels was analysed in 37 patients suffering from deep vein thrombosis and participating in the PERSIST trial. Plasma gamma-glutamyl-transferase, aspartate aminotransferase and alanine aminotransferase were determined prior to enoxaparin treatment (screening), prior to randomization (baseline) and once weekly during the 12-week treatment period. Patients were initially treated with weight-adjusted enoxaparin for 4-7 days and then randomized to either idraparinux (2.

Algorithms for the diagnosis of deep-vein thrombosis in patients with low clinical pretest probability.

The objective of this current trial was to evaluate the rate of deep-vein thrombosis (DVT) in patients after low clinical risk stratification and to evaluate the value of D-dimer and different imaging techniques in the diagnostic algorithm. A total of 99 consecutive patients were included in this prospective trial. After clinical risk assessment, D-dimer was determined.